Carboplatin

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

Carboplatin Chemical Structure

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Size Price Stock Quantity  
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The BRCA1-mutated TNBC cell lines MDA-MB-436 and HCC1937 were treated with CBP (10 μM) plus GEM (100 nM) combined with or without olaparib (10 μM) for the indicated times, and then, the cell viability was determined with an MTT assay. The results show data from six independent experiments expressed as the mean ± SD. p < 0.05.

    Sci Rep, 2017, 7:42319. Carboplatin purchased from Selleck.

    Detection of apoptotic responses was found to increase in epimorphin-treated  A1847 with increasing concentrations of carboplatin compared to those of the untreated controls. Data were normalized to the controls and are represented as means ± S.D. [*p<0.05 compared with control]. Images of apoptotic cells were captured at 10X magnification, with at least 3 images per well, using an upright phase-contrast microscope (T3.15A; Fisher Scientific).

    PLoS One 2012 8, e72637. Carboplatin purchased from Selleck.

  • A. MCF10A-Ras overexpressing a vector control or the gene of interest (GeneX), or MCF7 expressing a scramble or a siRNA for the geneX were treated with DMSO or with Carboplatin for 24h. Resistant colonies were allowed to grow for 2 weeks, and are then stained with Crystal Violet. B. Quantification of the results.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Carboplatin for 48h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.
Features A DNA synthesis inhibitor.
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jJblIuOjYkgJpOwG0> NWrjOIhnPzJiaB?= M3;pXYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NX\0XJpuOjZzM{exNFU>
Tca8113/CBP  M{f5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTBdIw5Oi1{NfMAje69VQ>? NVHjcXVIPzJiaB?= MXPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MnrjNlYyOzdzMEW=
Tca8113/PYM  M2HJR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rPOFIuOjYkgJpOwG0> NIf5T2U4OiCq MWHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MnLONlYyOzdzMEW=
SKOV3 MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\KelM3PjBibXevcYw> MYKxMVUh\A>? M3zwUIlvcGmkaYTzJINmdGxidnnhZoltcXS7IITpcYUh\GWyZX7k[Y51dHl? NH7nTGIzPjF|N{C0Ny=>
SKOV3 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[wMVQh|rypL33s NGXsdIUzPC92OD:3NkBp NHH5e2dqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 NW\vU|NrOjZzMkWyO|M>
SKOV3 MkjzRZBweHSxc3nzJGF{e2G7 M3nR[FIh|rypL33s MmLGOFghcA>? MXLpcoR2[2W|IHHwc5B1d3Orcx?= M4PWNlI3OTJ3Mkez
OSA MorrR4xwdm:pZX7pZ{BCe3OjeR?= NYfYOJg{Oi53L{Wg{txO MWny[ZN2dHS|IHnuJIxwf2W{IHPvcI9vgSCob4LtZZRqd25iYYOgZ49ueGG{ZXSgeI8h\Wm2aHXyJGJOUTFic3nSUmEhfHKnYYTt[Y51 MXuyOlEyODZ{MB?=
A549 NX;tSItITnWldHnvckBCe3OjeR?= M3z1ZVAwOjVxNUCg{txO NIO2dWwzPCCq MXLkc5dvemWpdXzheIV{KG2rUj2yNFUh\XiycnXzd4lwdsLi NUPWfpp1OjV7MUezNVc>
H1975 Mlr0SpVkfGmxbjDBd5NigQ>? MUmwM|I2NzVyIN88US=> MXOyOEBp NFOwWWlld3ewcnXneYxifGW|IH3pVk0zODViZYjwdoV{e2mxbtMg M{HkNlI2QTF5M{G3
A549 NH;VO4dHfWO2aX;uJGF{e2G7 NWDYc3JbOC9{NT:1NEDPxE1? NF3BNoUzPCCq NH\OSXd2eHKnZ4XsZZRmeyCvaWKtNlE5KGW6cILld5Nqd25? NYnCXVdDOjV7MUezNVc>
H1975 NFuzbZBHfWO2aX;uJGF{e2G7 NEnJNnIxNzJ3L{WwJO69VQ>? MlXkNlQhcA>? M2fO[JVxemWpdXzheIV{KG2rUj2yNVgh\XiycnXzd4lwdg>? MWGyOVkyPzNzNx?=
A549 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDMNlUh|ryP MVeyOEBp NWfnSmxmcW6qaXLpeJMh[2WubDDndo94fGh? MkLTNlU6OTd|MUe=
H1975 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jmc|I2KM7:TR?= MkLSNlQhcA>? MorFbY5pcWKrdIOgZ4VtdCCpcn;3eIg> M{C3XlI2QTF5M{G3
MDA-MB-231 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnVcYJsOC1{MkCg{txoN22u MWG3NkBp MoXlTWM2OMLiPTC4OkDPxE1? NGG2U5EzPTh|N{[5NS=>
T47D MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS3NE0zOjBizsznM41t NVLIXHpZPzJiaB?= M2rQOGlEPTEEoE2gOFgvQSEQvF2= MX6yOVg{PzZ7MR?=
LCTCC NEXZ[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv3TWM2OD1|LklihKnDvU1? MV:yOVc4OzF4Nx?=
MCTCC NYnuNVdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTlTWM2OD1{LklihKnDvU1? NGno[5MzPTd5M{G2Oy=>
MegTCC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTRwMfMAjeK2VQ>? MnPUNlU4PzNzNke=
MonoTCC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW5b2pVUUN3ME21MlbjiIoEtV2= NEDPXVYzPTd5M{G2Oy=>
MCF7 M3nTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTQO28zOCEQvF2= NYn0OlNHPzJiaB?= M371S4lv\HWlZYOgZ4VtdCCmZXH0bEBw\iCKUEJOtk1l\XCuZYTl[EBOS0Z5IHPlcIx{ M{HNUlI2PzZ7MEK1
A-549  MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTqUo8xNjVizszN NXvYUHhUOjRiaB?= M2rqS2ROW00EoB?= NV3LVZh2cW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> MnPnNlU4PTV4OUC=
A-549  MXPBdI9xfG:|aYOgRZN{[Xl? NYftOphCOC53IN88US=> M2r1VFQ5KGh? NHS5NYFFVVORwrC= M3;QOZNpd3e|IHXhdox6KGGyb4D0c5NqeyCoZXH0eZJmeyCrbnPseYRqdmdiYnzlZoJqdmdiYX7kJINpem:vYYTpckBkd26mZX7zZZRqd25? M4DQV|I2PzV3Nkmw
A-549  MmPsSpVkfGmxbjDBd5NigQ>? MYGwMlUh|ryP M1XlOVQ5KGh? NX3PeZZbTE2VT9Mg NFXmV4F{cG:5czDhZoVzemGwdDDtbYNzd3S3YoXs[UBlcXO{dYD0bY9v MXKyOVc2PTZ7MB?=
A-549  NGLZWGlHfWO2aX;uJGF{e2G7 M1LBbFAvPSEQvF2= NELwPW81QCCq M4\MfmROW00EoB?= M4XrUolvcGmkaYTzJI9nKGOnbHygcYloemG2aX;uxsA> M1;HXFI2PzV3Nkmw
RMG-1 NEC1eGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\STWM2OD1{OD64JOKyKDNwNjDt[{9N M3nUSFI2PzJ4OUGz
FN-RMG-1 MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\wWlNQUUN3ME20NE42KMLzIESuNkBu\y:OCjFOwG0> NVXRW5ZQOjV5Mk[5NVM>
RMG-1-hFUT MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorTTWM2OD13OD6xJOKyKDJwNDDt[{9N MUOyOVczPjlzMx?=
FN-RMG-1-hFUT MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHETWM2OD1zMUiuPEDDuSBzMz64JI1oN0x? NFfhVnQzPTd{NkmxNy=>
CHP-134  NXXQdVVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGwfnB2OSEQvF2= NEnwNlBFVVORwrC= NVzwVpY5cW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz M{noWVI2PjV6NE[z
IMR-32 MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzpUXMyKM7:TR?= M1\yeGROW00EoB?= M2TocYlvcGmkaYTzJJNq\26rZnnjZY51KGOnbHyg[5Jwf3SqIHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? MYqyOVY2QDR4Mx?=
CHP-134  MmO1SpVkfGmxbjDBd5NigQ>? MlrlNVAh|ryPwrC= NHL0PFRFVVORwrC= M2ToTIlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBIW0t{OEOwN|cy NIX0WVEzPTZ3OES2Ny=>
IMR-32 NWTCc4dbTnWldHnvckBCe3OjeR?= MVSxNEDPxE4EoB?= NVS2dodTTE2VT9Mg MWrpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigS3NMOjh|MEO3NS=> MXqyOVY2QDR4Mx?=
A549 NYTCXmh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXewSYlSOC5{LUSwNFAh|ryP MXK3NkBp M3LZPWlEPTB;MUK2JOKyKDVwMDFOwG0> NELubXozPTZ{NUK0Ny=>
A549/CDDP NI\aWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\JVIoxNjJvNECwNEDPxE1? NGHObGk4OiCq M{jUe2lEPTB;MkSwxsDDucLiNEWuO{DPxE1? NF;FVlQzPTZ{NUK0Ny=>
H460  NHmwUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTaNlQhcA>? MXjEUXNQ NXj5[5U5UUN3ME23Mlkh|ryP M1z1XFI2PTl7OUm1
H460  MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEexTZo4NjlizszN MmjLNlQhcA>? M1jMTWROW09? MYLzbI94eyCjIILh[Ilwe2Wwc3n0bZpqdmdiZX\m[YN1KHSxIGitdoF6ew>? NF[0b3ozPTV7OUm5OS=>
NRK-52E M2DaNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTxU|k5PzMEoHlCpC=> MYPJR|UxRTFyMDFCtUAyOi57IN88US=> NHLj[2QzPTV4NU[wNy=>
RGE M1\5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17LN|czyqCqwrC= NGfOXIRKSzVyPUKyJOKyKDdwNDFOwG0> MoiwNlU2PjV4MEO=
NRK-52E M4\LTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Dq[FczyqCqwrC= MnfnTWM5OD1zN{mgxtEhQS53IN88US=> NFrNc2szPTV4NU[wNy=>
RGE M4LKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXTSlBpPzMEoHlCpC=> M4iybGlEQDB;NkOgxtEhPy52IN88US=> MViyOVU3PTZyMx?=
SK-OV-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\VO|IhcA>? MkjTTWM2OD1zMESuPEDPxE1? MXeyOVUzODF|Mh?=
ES-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWS3NkBp NFnUTJpKSzVyPUG0MlYh|ryP MVGyOVUzODF|Mh?=
OVCAR-8 Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nGcFczKGh? M4iwNmlEPTB;OU[uNEDPxE1? NVjMNYs4OjV3MkCxN|I>
3AO NX7RcW97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVK3NkBp NYfuToJwUUN3ME22N{41KM7:TR?= NEfRc4gzPTV{MEGzNi=>
A2780 NHfQ[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPFO|IhcA>? NHjCcJBKSzVyPUG0OU44KM7:TR?= NHHiNYkzPTV{MEGzNi=>
SW626 NUTzdJhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG3NkBp MUfJR|UxRTl5LkCg{txO MkTINlU2OjBzM{K=
OVCAR-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\FRVE4OiCq NVTNeWlJUUN3ME2zNk43KM7:TR?= Mn3TNlU2OjBzM{K=
A549 NFGwVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF3MT61OkDDuSB3Mz6wOkDPxE1? MljzNlUzPzd2NkG=
4T1 M{\Ccmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTh2Lk[yJOKyKDNyLkC1JO69VQpizszN M1T3Z|I2Ojd5NE[x
BALB/3T3 M1rtSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z6OmlEPTB;MUSuN|AhyrFiNj62PEDPxE1? MXKyOVI4PzR4MR?=
B16 MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP5Sm5TUUN3ME22OE4{OCEEsTC2MlgyKM7:TR?= NWC4dpFKOjV{N{e0OlE>
DU 145 NH\FWZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTN3LkC0JOKyKDF5LkW0JO69VQ>? MoXWNlUzPzd2NkG=
FaDu NIHXNZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;lN4VKSzVyPUS1MlM6KMLzIEGxMlUxKM7:TR?= NVj0bWZ[OjV{N{e0OlE>
HCV-29T NWHlcHRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfXPZNKSzVyPUS4MlU4KMLzIEKyMlQ6KM7:TR?= NXzIUIxGOjV{N{e0OlE>
HL-60 M1rITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TnN2lEPTB;MUGuNVAhyrFiND60O{DPxE1? MX2yOVI4PzR4MR?=
HT-29 M3O4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzTTWM2OD16OT6xOkDDuSBzOD64OkDPxE1? MljTNlUzPzd2NkG=
H146 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ry[2lEPTB;NEmuOuKyOTNwMTFOwG0> M{PN[FI2OTJ2Mkiy
H187 M2\tPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrGTWM2OD1zMj63xtEzNjdizszN NFPNepMzPTF{NEK4Ni=>
H128 NX65d2l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;scGlEPTB;MUC2MlTDuTlwNjFOwG0> M2rqVVI2OTJ2Mkiy
H69 NFriSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlu5TWM2OD15Nj65xtEzPy56IN88US=> MWmyOVEzPDJ6Mh?=
H209 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDicY1JUUN3ME2yOVgvOcLzOUmuPEDPxE1? MYCyOVEzPDJ6Mh?=
DMS153 MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTV5LklCtVkvOiEQvF2= MoLVNlUyOjR{OEK=
H526 M3HOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2mxTmlEPTB;Nz6yxtEyNjdizszN NH\mN4QzPTF{NEK4Ni=>
DMS114 MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfyWW9uUUN3ME24OU45yrFzMj64JO69VQ>? NYn1Z5VPOjVzMkSyPFI>
DMS53 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDzTWM2OD1zNE[uNuKyOzZwNDFOwG0> MWWyOVEzPDJ6Mh?=
HeLa NIT4OpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnPOU05OCEQvF2= NFfTUpNqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NEPte5MzPTFyOUO2NC=>
MCF-7 MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTNdphXPS16MDFOwG0> NXnncYtVcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? Mn7tNlUyODl|NkC=
MDA-MB-231 M2TRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHOc3k2NThyIN88US=> NFHHepFqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MmrvNlUyODl|NkC=
CaOV3 NFPDdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;EeYs4OiCq Mo\hTWM2OD16Nj6xJO69VQ>? NYfaWnRxOjVyNki4OFk>
OVCAR-3 M3L6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXPO|IhcA>? NF\tbZhKSzVyPUG3PU42KM7:TR?= MmTINlUxPjh6NEm=
OVCAR-5 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXu3NkBp M17JU2lEPTB;N{WuO{DPxE1? MW[yOVA3QDh2OR?=
SKOV-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfJPWRYPzJiaB?= NFfZN5BKSzVyPUWwOEDPxE1? NETWSmczPTB4OEi0PS=>
OVCAR-4 MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUK3NkBp MoXvTWM2OD1{OUCuOkDPxE1? MYqyOVA3QDh2OR?=
OVCAR-8 MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu2SoM4OiCq MXXJR|UxRTZ7MD6yJO69VQ>? NYPEdox7OjVyNki4OFk>
MA148 NH;2ZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDsNlQhcA>? M2jS[mlEPTB;OEOuOwKBkcLz4pEJNU41KM7:Zz;tcC=> Mkm3NlQ5OzFyOUG=
A549 M3\u[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nBdVI1KGh? NUHEZoJ1UUN3ME23O|YvOOLCidMx5qCKOS57IN88[{9udA>? MliwNlQ5OzFyOUG=
MDA-MB-231 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDrVmZuOjRiaB?= M3j5TWlEPTB;N{S4MlDjiIoEsfMAjVEvOSEQvHevcYw> MXSyOFg{OTB7MR?=
NCI-ADR/RES  NGjQ[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2yOEBp NFjMT4NKSzVyPUG3OVMvOOLCidMx5qCKPC52IN88[{9udA>? Moi3NlQ5OzFyOUG=
MA148 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\OR241QCCq NYC5[XVwUUN3ME2yPE4y6oDLwsJihKkyNjBizsznM41t Mln2NlQ5OzFyOUG=
A549 NVXYT5JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXWy[GpmPDhiaB?= NF3qbZVKSzVyPUGxPE4x6oDLwsJihKkyNjJizsznM41t NWflNVlOOjR6M{GwPVE>
MDA-MB-231 NEDIdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P6[|Q5KGh? NHX5W3JKSzVyPUG4N{4x6oDLwsJihKkyNjJiIN88[{9udA>? NYrJOVNjOjR6M{GwPVE>
NCI-ADR/RES  MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr1d|VyPDhiaB?= MoW5TWM2OD1zOUOuNQKBkcLz4pEJNU46KM7:Zz;tcC=> MVuyOFg{OTB7MR?=
MA148 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;xW5JLPzJiaB?= MnHqTWM2OD1zMz635qCKyrIkgJmxMlIh|rypL33s NF;5W2EzPDh|MUC5NS=>
A549 NYrFeHZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rReFczKGh? NWXmPVZYUUN3ME22OE4{6oDLwsJihKkyNjFizsznM41t NVPkNpc1OjR6M{GwPVE>
MDA-MB-231 M2DEc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO1[VBVPzJiaB?= MVvJR|UxRTl7LkZihKnDueLCiUGuNUDPxGdxbXy= MYqyOFg{OTB7MR?=
NCI-ADR/RES  M{DkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfJOGpWPzJiaB?= MXvJR|UxRTN5LkVihKnDueLCiUGuO{DPxGdxbXy= NXS2T29bOjR6M{GwPVE>
A549 NHvvdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv4RpFwPzJiaB?= NY\ocHpxTE2VTx?= NHHacWRKSzVyPUG1Nk41ODlizszN M3\lSFI1PzJzM{Kz
NCI-H157 NXi4fY5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13yXFczKGh? Ml7CSG1UVw>? MoG0TWM2OD16OT65O|ch|ryP MXiyOFczOTN{Mx?=
PC9 M33vR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTzc5BkPzJiaB?= M2e3bWdEPTB;N{GuOuKyQS53INM1US=> NXfkXZBiOjR4MUi4NFk>
A549  MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInwRmM4OiCq NYLaXFJlT0N3ME2xN|bDuTNzLk[gxtVOyqB? MXiyOFYyQDhyOR?=
PC9 MkTtRZBweHSxc3nzJGF{e2G7 NHLybowyODBiwsXN M{L5fFczKGh? M3\TXYlv\HWlZYOgZZBweHSxc3nz MnKyNlQ3OTh6MEm=
A549  MWjBdI9xfG:|aYOgRZN{[Xl? MVmxNFAhyrWP NYLTOVB1PzJiaB?= MXPpcoR2[2W|IHHwc5B1d3Orcx?= NF[2R3czPDZzOEiwPS=>
A549 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK1bWYzPCCq NV73dpVPUUNzME2xMlQ4PiCwTR?= MW[yOFM6PjR|Nx?=
H1299 NUfRPGN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLIRYIzPCCq NFzlbHVKSzFyPUCuOFQ{KG6P NGXSb|czPDN7NkSzOy=>
HCC15 M4PzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[w[lI1KGh? MluzTWMyOD1yLkO0OkBvVQ>? MX:yOFM6PjR|Nx?=
H157 NV7BWHlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTTNlQhcA>? MnHKTWMyOD1yLkixJI5O NFLGR44zPDN7NkSzOy=>
A2780 Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF2LkFihKnDueLCiUGuOEDPxE1? MmTONlQzODl4OUO=
A2780cisR MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILYOWhKSzVyPUS4MlnjiIoEsfMAjVMvQSEQvF2= NXO3T4ZUOjR{MEm2PVM>
A2780ZD0473R NXzsW3loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTuTWM2OD14ND625qCKyrIkgJmzMlIh|ryP M4\0PFI1OjB7Nkmz
SKOV-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTR|LkVihKnDueLCiUOuPUDPxE1? NV;xdXIxOjR{MEm2PVM>

... Click to View More Cell Line Experimental Data

In vivo In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Formulation: Carboplatin is dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water.
  • Dosages: ≤60 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
water
14mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage powder
Synonyms JM-8, CBDCA, NSC 241240

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT02124902 Recruiting Triple Negative Breast Neoplasms Washington University School of Medicine July 7, 2014 Phase 2
NCT02941523 Not yet recruiting Cancer Noxopharm Limited March 6, 2017 Phase 1|Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03032614 Not yet recruiting Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation The University of Texas Health Science Center at San Antonio March 31, 2017 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

Related Antibodies

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID